GPR35-Active Collagen Peptides for Intestinal and Anti-Inflammatory Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies do not effectively address the decline in collagen production with age, leading to aging-related diseases and the need for external collagen intake, and there is a lack of bioactive collagen peptides that can regulate intestinal metabolic functions and relieve inflammation.
Innovation Solution
Development of collagen peptides with GPR35 activity produced through microbial fermentation by Lactobacilluseae family strains, specifically L. paracasei, L. plantarum, and L. salivarius, for use in food, cosmetics, and pharmaceutical compositions to improve intestinal function, relieve inflammation, and promote wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If collagen is ingested through food to address age-related collagen decline, then collagen production can be supplemented, but the effectiveness is limited without bioactive peptides that can regulate intestinal metabolic functions
Solution Approach 1:
The patent changes the molecular weight parameter of collagen to produce peptide fragments in specific size ranges (0.5-10 kDa), which fundamentally alters their biological activity. These smaller peptide fragments can bind to GPR35 receptors in the intestine, providing the regulatory function that larger collagen molecules cannot achieve.
Solution Approach 2:
The patent segments collagen into smaller peptide fragments through controlled hydrolysis by microbial proteases. This segmentation creates multiple bioactive peptides with specific functions, including GPR35 binding activity, rather than using intact collagen molecules.
2Quantity of substance
If conventional collagen supplements are used, then collagen intake is increased, but they lack the ability to relieve inflammation and promote wound healing effectively
Solution Approach 1:
The patent changes the molecular structure parameter by producing specific peptide sequences through controlled hydrolysis. These peptides have molecular weights of 0.5-10 kDa and specific amino acid sequences that enable them to bind to GPR35 receptors, triggering anti-inflammatory and wound healing pathways that conventional collagen supplements cannot activate.
Solution Approach 2:
The patent introduces GPR35-binding peptides as intermediary molecules that mediate between collagen intake and physiological effects. These peptides act as signaling molecules that bind to GPR35 receptors, translating collagen presence into specific biological responses including reduced inflammation and enhanced wound healing.
3Manufacturing precision
If chemically synthesized peptides are used, then specific bioactive sequences can be obtained, but the production cost and complexity increase significantly
Solution Approach 1:
The patent employs microbial proteases that naturally occur in Lactobacilluseae family bacteria to perform the hydrolysis of collagen. The microorganisms themselves provide the enzymatic activity needed to produce bioactive peptides, eliminating the need for external enzyme additions or complex chemical synthesis processes.
Solution Approach 2:
The patent changes the production method from chemical synthesis to microbial fermentation, fundamentally altering how bioactive peptides are manufactured. By controlling fermentation conditions and selecting specific microbial strains, the process achieves high manufacturing precision for peptide sequences while maintaining simplicity in the overall production workflow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The collagen peptides with GPR35 activity enhance intestinal function, reduce inflammation, and promote wound healing, providing a bioactive solution for aging-related issues and inflammatory diseases.
Implementation Method 1
collagen peptides obtained by cultivation with one or more microorganisms selected from Lacticaseibacillus paracasei, Lactiplantibacillus plantarum, and Ligilactobacillus salivarius
Implementation Method 2
collagen peptides produced through microbial fermentation
Data Source
AI summary
The present invention relates to GPCR ligand collagen peptides produced through microbial fermentation, and in particular, to a method of preparing collagen peptides obtained by culturing a microorganism, peptides prepared by the method, and a composition including the peptide as an active ingredient; and a composition for improving intestinal function, relieving inflammation, and/or promoting wound healing, and a method of preparing the composition.